Company release, 8 February 2022 at 4:00 p.m. (EET)
The Board of Directors of Nightingale Health Plc (“Nightingale”) has in its meeting on November 8, 2021, approved a request of shareholders to convert 661,246 Series A shares of Nightingale to Series B shares in accordance with Article 5 in the Articles of Association.
As a result of the conversion of shares, the number of the Nightingale’s Series A shares is 21,518,422, Series B shares is 37,880,735 and EMP shares is 1,482,580. The conversion does not affect the total amount of shares which is 60,881,737. The number of votes of Nightingale’s shares after the conversion is 253,064,955.
The conversions of shares were registered in the Trade Register on February 8, 2022. The converted shares will be listed on the Nasdaq First North Growth Market Finland marketplace together with the old shares as of February 9, 2022.
For further information, please contact:
Teemu Suna, CEO
Oaklins Merasco Ltd, tel. +358 9 6129 670
Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.